Evidence map›Paper›PMID 32680547›Full record

ArticleJournal of neuroinflammation2020

Nuclear factor kappa B activation appears weaker in schizophrenia patients with high brain cytokines than in non-schizophrenic controls with high brain cytokines.

Caitlin E Murphy, Adam J Lawther, Maree J Webster, Makoto Asai, Yuji Kondo, Mitsuyuki Matsumoto, Adam K Walker, Cynthia Shannon Weickert

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. The role ofEpigenetics · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Steroid treatment suppresses the CD4Scientific reports · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Caitlin E MurphySchizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Randwick, Sydney, NSW, 2031, Australia.ORCID http://orcid.org/0000-0003-0216-6912
Adam J LawtherSchizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Randwick, Sydney, NSW, 2031, Australia.
Maree J WebsterStanley Medical Research Institute, Kensington, Maryland, USA.
Makoto AsaiAstellas Pharma Inc., Drug Discovery Research, Tsukuba, Japan.
Yuji KondoAstellas Pharma Inc., Drug Discovery Research, Tsukuba, Japan.
Mitsuyuki MatsumotoAstellas Pharma Inc., Drug Discovery Research, Tsukuba, Japan.
Adam K WalkerSchizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Randwick, Sydney, NSW, 2031, Australia.
Cynthia Shannon WeickertSchizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Randwick, Sydney, NSW, 2031, Australia. c.weickert@neura.edu.au.
Astellas Pharma (Japan) · JPUNSW Sydney · AUNeuroscience Research Australia · AUStanley Medical Research Institute · USSUNY Upstate Medical University · US

Funding

Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
Department of Education, Skills and Employment (AU) Research Training ProgramNational Breast Cancer Foundation Australia PF-15-014National Health and Medical Research Council 1117079National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health R28AA012725NIAAA NIH HHS R28 AA012725
6 · The paper itself

Abstract

backgroundHigh inflammation status despite an absence of known infection characterizes a subpopulation of people with schizophrenia who suffer from more severe cognitive deficits, less cortical grey matter, and worse neuropathology. Transcripts encoding factors upstream of nuclear factor kappa B (NF-κB), a major transcriptional activator for the synthesis of pro-inflammatory cytokines, are increased in the frontal cortex in schizophrenia compared to controls. However, the extent to which these changes are disease-specific, restricted to those with schizophrenia and high-neuroinflammatory status, or caused by loss of a key NF-κB inhibitor (HIVEP2) found in schizophrenia brain, has not been tested.

methodsPost-mortem prefrontal cortex samples were assessed in 141 human brains (69 controls and 72 schizophrenia) and 13 brains of wild-type mice and mice lacking HIVEP2 (6 wild-type, 7 knockout mice). Gene expression of pro-inflammatory cytokines and acute phase protein SERPINA3 was used to categorize high and low neuroinflammation biotype groups in human samples via cluster analysis. Expression of 18 canonical and non-canonical NF-κB pathway genes was assessed by qPCR in human and mouse tissue.

resultsIn humans, we found non-canonical upstream activators of NF-κB were generally elevated in individuals with neuroinflammation regardless of diagnosis, supporting NF-κB activation in both controls and people with schizophrenia when cytokine mRNAs are high. However, high neuroinflammation schizophrenia patients had weaker (or absent) transcriptional increases of several canonical upstream activators of NF-κB as compared to the high neuroinflammation controls. HIVEP2 mRNA reduction was specific to patients with schizophrenia who also had high neuroinflammatory status, and we also found decreases in NF-κB transcripts typically induced by activated microglia in mice lacking HIVEP2.

conclusionsCollectively, our results show that high cortical expression of pro-inflammatory cytokines and low cortical expression of HIVEP2 in a subset of people with schizophrenia is associated with a relatively weak NF-κB transcriptional signature compared to non-schizophrenic controls with high cytokine expression. We speculate that this comparatively milder NF-κB induction may reflect schizophrenia-specific suppression possibly related to HIVEP2 deficiency in the cortex.

Indexed as

AdultAnimalsBrainCytokinesDNA-Binding ProteinsFemaleHumansMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMiddle AgedNF-kappa BSchizophreniaTranscription FactorsCytokinesDNA-Binding ProteinsHIVEP2 protein, humanHivep2 protein, mouseNF-kappa BTranscription FactorsSchizophrenia NF-κB inflammation cortex HIVEP2 Schnurri-2

Identifiers

PMID32680547
PMCPMC7368759
OpenAlexW3043342415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.